Native Top-Down Mass Spectrometry Combined with High-Resolution Charge Variant Analysis of Trastuzumab Originator and Biosimilars
Journal of the American Society for Mass Spectrometry · 2026
DOI: 10.1021/jasms.5c00438 ↗At a glance
Journal article in Journal of the American Society for Mass Spectrometry, 2026. Written by Corentin Beaumal and 3 co-authors. Institution: Characterization and Comparability Laboratory, NIBRT - National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Blac…. Major MEDLINE topics: Trastuzumab, Biosimilar Pharmaceuticals, Mass Spectrometry. Cited 1 times so far (Crossref); 88 references. The full text is freely available (open access, CC BY 4.0). Funded by: Thermo Fisher Scientific, National Institute for Bioprocessing Research and Training.
Abstract (original language)
Comprehensive characterization of monoclonal antibody (mAb) charge heterogeneity is essential to ensure product quality, maintain batch consistency and support biosimilar development. Charge variant analysis (CVA) is widely used to separate acidic and basic proteoforms from the main species. However, cation-exchange chromatography coupled to mass spectrometry provides limited information and cannot localize the post-translational modifications (PTMs) responsible for mAb heterogeneity. Here, the coupling of pH-gradient CVA with native top-down mass spectrometry (TD-MS) for proteoform-specific analysis of trastuzumab is presented. Individual charge variants were chromatographically separated under native conditions and directly fragmented on the chromatographic time scale using higher-energy collision dissociation (HCD), electron-transfer dissociation (ETD) and ultraviolet photodissociation (UVPD). The addition of proton-transfer charge reduction (PTCR) helped reduce spectral congestion and enhanced the detection of high-mass fragment ions, resulting in improved sequence coverage. This workflow enabled the complete sequencing of the complementarity-determining region (CDR) 3 and the direct identification and insights into the location of key PTMs at the intact-protein level, including deamidation, succinimide and N-terminal pyroGlu for individual proteoforms. Comparison of five trastuzumab samples (originator and biosimilars) demonstrated high reproducibility in fragmentation patterns, sequence coverage and variant assignment, highlighting the robustness of the method. Although limitations remain due to the challenges of fragmenting intact mAbs under native conditions, this work establishes a proof of concept for CVA native TD-MS characterization of mAbs to complement bottom-up and middle-down analyses, and has potential for broad applicability for antibody-based biopharmaceuticals.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Characterization and Comparability Laboratory, NIBRT - National Institute for Bioprocessing Research and Training, Foster Avenue, Mount Merrion, Blackrock, Dublin A94 X099, Ireland.
- Thermo Fisher Scientific, 11 Neuhofstrasse, 4153 Reinach, Switzerland.
- School of Chemical and Bioprocess Engineering, University College Dublin, Belfield, Dublin D04 V1W8, Ireland.
ORCID profiles: Corentin Beaumal, Jonathan Bones
Funding
- Thermo Fisher Scientific
- National Institute for Bioprocessing Research and Training
Cite
APA
Beaumal, C., Srzentić, K., Carillo, S., & Bones, J. (2026). Native Top-Down Mass Spectrometry Combined with High-Resolution Charge Variant Analysis of Trastuzumab Originator and Biosimilars. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.5c00438
Vancouver
Beaumal C, Srzentić K, Carillo S, Bones J. Native Top-Down Mass Spectrometry Combined with High-Resolution Charge Variant Analysis of Trastuzumab Originator and Biosimilars. Journal of the American Society for Mass Spectrometry. 2026. doi:10.1021/jasms.5c00438
BibTeX
@article{Beaumal2026,
author = {Beaumal, Corentin and Srzentić, Kristina and Carillo, Sara and Bones, Jonathan},
title = {Native Top-Down Mass Spectrometry Combined with High-Resolution Charge Variant Analysis of Trastuzumab Originator and Biosimilars},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2026},
doi = {10.1021/jasms.5c00438}
}
EUVIMED